We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MS Drug Blocks HIV Infection and Transmission in Human Immune Cells

News   Aug 14, 2020 | Original story from George Washington University

 
MS Drug Blocks HIV Infection and Transmission in Human Immune Cells

An immunomodulatory drug called fingolimod, which is approved for the treatment of multiple sclerosis, blocks human immunodeficiency virus (HIV) infection and transmission in human immune cells, according to a study published August 13 in the open-access journal PLOS Pathogens by Postdoctoral Fellow Rachel Resop and Assistant Professor Alberto Bosque of The George Washington University, and colleagues. These preliminary findings suggest that this compound may be a promising novel therapy for HIV treatment and prevention. Credit: NIAID. CC BY 2.0

 
 
Advertisement
 

RELATED ARTICLES

Study Finds Unique Genetic Variants in ADHD Patients From Different Ethnic Backgrounds

News

Researchers from Children’s Hospital of Philadelphia (CHOP) have shown there may be key genetic differences in the causes of attention-deficit hyperactivity disorder (ADHD) between African Americans and people of European ancestry, which may play an important part in how patients of different ethnic backgrounds respond to treatments for this condition.

READ MORE

Exercise Hormone May Modulate Genes Associated With SARS-CoV-2

News

A study conducted by researchers at São Paulo State University (UNESP) suggests that irisin, a hormone secreted from muscles in response to exercise, could have a therapeutic effect on COVID-19 patients.

READ MORE

Study Investigates Racial Disparities in Clinical Trial Recruitment

News

Scientists are increasingly turning to electronic-based recruitment methods to encourage participation in clinical trials. Little is known about how this use of technology compares to more traditional clinical trial recruitment strategies, and some researchers worry that an overreliance on technology has the potential to exclude an eligible and interested diverse participant population.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE